Xeris Biopharma Holdings (LTS:0A8E) Accounts Payable & Accrued Expense : $44.6 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Xeris Biopharma Holdings Accounts Payable & Accrued Expense?

Xeris Biopharma Holdings's quarterly accounts payable & accrued expense increased from Sep. 2024 ($35.1 Mil) to Dec. 2024 ($39.5 Mil) and increased from Dec. 2024 ($39.5 Mil) to Mar. 2025 ($44.6 Mil).

Xeris Biopharma Holdings's annual accounts payable & accrued expense declined from Dec. 2022 ($44.8 Mil) to Dec. 2023 ($40.3 Mil) and declined from Dec. 2023 ($40.3 Mil) to Dec. 2024 ($39.5 Mil).

Xeris Biopharma Holdings Accounts Payable & Accrued Expense Historical Data

The historical data trend for Xeris Biopharma Holdings's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Accounts Payable & Accrued Expense Chart

Xeris Biopharma Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

17.01

53.42

44.81

40.27

39.51

Xeris Biopharma Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															41.68	39.74	35.08	39.51	44.62

Xeris Biopharma Holdings Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Xeris Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (LTS:0A8E) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

XERS:USA 2B30:Germany

Address

1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607

Website

https://www.xerispharma.com

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Xeris Biopharma Holdings Headlines

No Headlines